Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Study Tracks How Targeted Cancer Treatment Works

By Drug Discovery Trends Editor | January 15, 2014

Leukemic cells before (left) and after treatment (right). The blue represents DNA in the nucleus; the red is nuclear corpus PML. These one are reorganized by the treatment targeting PML/RARA. (Source: Paris Diderot University/Inserm/ CNRS/AP-HP, Hugues de Thé)The mechanism of senescence– or premature cell aging– can have an anticancer effect. This new work, conducted by Hugues de Thé and his team (Paris Diderot University/Inserm/ CNRS/AP-HP), was published in Nature Medicine.
 
The study revealed that targeted treatments for acute promyelocytic leukemia, a rare form of blood cancer, cause a cascade of molecular events leading to cellular senescence and recovery. This action model could be activated in other types of cancers. 
 
The PML/RARA protein causes the proliferation of cancer cells in patients affected by acute promyelocytic leukemia. Existing targeted treatments combining a hormone (retinoic acid) and a poison (arsenic) result in permanent recovery for the majority of patients, without having a precise understanding of their action on cancer cells. Previous work by Hugues de Thé’s team has shown that the combination of arsenic and retinoic acid causes destruction of the PML/RARA protein and the elimination of leukemic stem cells. However, the link between these two events had yet to be understood.
 
The new research contributed the factors needed to understand that recovery. It demonstrated the unexpected involvement of a cascade of events leading to senescence. The aim of the treatment is to reach this final aging stage of the cells in order to render them incapable of multiplying.
 
During this targeted treatment, the researchers showed that the p53 protein, which determines cell death and survival, triggers senescence through the involvement of PML nuclear bodies. These spherical structures are present in normal cells but are disorganized by PML/RARA in leukemia. The treatment reorganizes them, activating p53 and triggering senescence. In this cascade of events (treatment, PML/RARA degradation, reformation of nuclear bodies, p53 activation), only one link has to be missing to block all the therapeutic effects.
 
It is this phenomenon that enables the elimination of diseased cells and leads to total recovery of the patient, using only combined retinoic acid/arsenic treatment. The absence of chemotherapy avoids many severe side effects.
 
This understanding of the cellular and molecular mechanism of recovery from acute promyelocytic leukemia opens prospects for activating this same PML/p53 pathway in other types of cancers.
 
Date: January 14, 2014
Source: Inserm

Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE